Initial assessment of meptazinol in the treatment of the pain of myocardial infarction/unstable angina.

Abstract

Meptazinol, a new analgesic agent, was used to treat chest pain in patients admitted to a coronary care unit with suspected myocardial infarction or unstable angina. A pilot study showed that meptazinol was effective in relieving pain in 15 out of 22 subjects. There were no adverse haemodynamic effects nor respiratory depression. Nausea and/or vomiting occurred with administration of the drug but as these symptoms may occur in patients with myocardial infarction who have not received any analgesia (Ingram et al., 1980), a cause and effect relationship cannot be inferred in this respect. The incidence of other side effects ascribed to meptazinol was low.

• Authors: T Sonecha, O Abdel-Hadi, E M Besterman, P H Kidner
• Journal: Postgraduate medical journal (Postgrad Med J) Vol. 59 Suppl 1 Pg. 57-9 ( 1983) ISSN: 0032-5473 [Print] England
• PMID: 6835892 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Azepines
• Meptazinol
• Cyclizine

Topics

• Angina Pectoris (drug therapy)
• Azepines (therapeutic use)
• Cyclizine (therapeutic use)
• Humans
• Injections, Intramuscular
• Injections, Intravenous
• Meptazinol (adverse effects, therapeutic use)
• Myocardial Infarction (complications)
• Pain (drug therapy, etiology)